Drug Profile

MT 1013

Alternative Names: MT-1013

Latest Information Update: 10 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Shaanxi Micot Technology Co
Class Peptides
Mechanism of Action Calcium-sensing receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase III Secondary hyperparathyroidism
No development reported Calcium metabolism disorders; Phosphorus metabolism disorders

Most Recent Events

05 Jan 2026 Everest medicines in-licenses MT 1013 from Shaanxi Micot Pharmaceutical Technology in China and Asia-Pacific excluding Japan
05 Jan 2026 Efficacy data from a phase II trial in Secondary hyperparathyroidism released by Shaanxi Micot Technology
30 Nov 2025 Phase-I clinical trials in Secondary hyperparathyroidism in China (Parenteral, Injection) (NCT07284043)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com